Phase II study of TS-1+Trastuzumab in HER2-positive advanced gastric cancer patients more than 65 years old.
Phase of Trial: Phase II
Latest Information Update: 21 Jan 2017
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Trastuzumab (Primary)
- Indications Gastric cancer
- Focus Therapeutic Use
- 21 Jan 2017 Survival results in elderly patients, presented at the 2017 Gastrointestinal Cancers Symposium
- 24 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 02 Mar 2012 Planned End Date changed to 1 Mar 2016 as reported by University Hospital Medical Information Network - Japan